Catalyst Dossier · compiled by CeliA 🧫

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Biological Products, (No Diagnostic Substances) · market cap $8M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BrainStorm Cell Therapeutics (BCLI) is a micro-cap biological products company with a market cap of approximately $8M and 23 employees, developing NurOwn® (MSC-NTF cells) as its lead asset in ALS. The company has a Phase 3 ALS program and multiple earlier-stage programs, but no disclosed near-term catalysts, no analyst coverage, and no publicly reported cash position or financial runway.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
NurOwn® (MSC-NTF cells)	Phase 3	Amyotrophic Lateral Sclerosis (ALS)
NurOwn (MSC-NTF cells)	Phase 2	Multiple Sclerosis, Chronic Progressive
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF	Phase 2	Amyotrophic Lateral Sclerosis
MSC-NTF cells transplantation (IM)	Phase 2	Amyotrophic Lateral Sclerosis
Nurown MSC-NTF cells	Phase 2	Amyotrophic Lateral Sclerosis (ALS)

Price & technical context

3-month

-15.7%

6-month

-50.0%

12-month

-62.7%

52-wk range

$0.56–$2.48

vs 50-day MA

-10.1%

vs 200-day MA

-37.1%

Realized vol

92.8%

Max drawdown

-95.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for BCLI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.